With the commercial development at its facility in Mirfield, CPS expands in the areas of activated mPEG manufacturing and in the development and manufacture of New Chemical Entities (NCE) APIs for use in pre-clinical research.
Dr. Reddy’s Pharmaceutical Services and Active Ingredients business president Dr. Ananthanarayanan said the expansion will enable the company to provide a finer network of cGMP manufacturing to support its global customer base.
"PEGylation is one area where we felt the need for expanding our capabilities. We have invested in multiple technology areas and the expansion will add significant value in the areas of mPEGs and cGMP API manufacturing," Dr. Ananthanarayanan added.
The company expects that the expansion will enable it to manufacture its PEGtech range at commercial metric tonne scale quantities and beyond in a cGMP environment.
The facility is equipped with DCS computer control systems and has been designed with the latest manufacturing compliance standards in mind, according to the company.